Content Type
Tuesday
January 13
2015
Monday
May 12
2014
Market dynamics is emerging as a key to delivering health care to the base of the pyramid. NextBillion Health Care is launching a new initiative in recognition of that fact.
Tuesday
January 28
2014
Traditional ways of viewing diagnostics and drugs separately are starting to blur, especially in the developed world. But new business and partnership models are needed if these boundary-spanning new technologies are to reach low-income countries.
Tuesday
April 1
2014
The lack of access to safe sanitation and clean water holds back social and economic development through negative impacts on health, education and livelihoods. Research shows the situation can be improved through interventions that place an emphasis on the end beneficiary and leverage local private-public expertise in design and delivery.
Tuesday
May 13
2014
Market dynamics is a hot topic these days. Why? Because if we understand market dynamics, we’re better able to design, implement, monitor and evaluate interventions that improve health outcomes by improving the “health” of markets
Monday
May 19
2014
Lila Cruikshank / Andrea Taylor
Counterfeit drugs kill hundreds of thousands every year. Technologies designed to help alleviate this problem also have have relevance in supply chains and delivery challenges.
Guest Articles
Wednesday
May 28
2014
Medical equipment manufacturers face challenges selling in low-income countries. That led Gradian Health Systems to adopt a foundation-owned social enterprise model, allowing it to function as both a commercial entity and a nonprofit.
Guest Articles
Thursday
May 29
2014
Like a traditional business, Gradian spends money on market creation for its anesthesia machine. Unlike a traditional business, however, the company doesn’t expect to recoup that cost; it’s paid for with philanthropic funding so Gradian can offer the machine at as low a cost as possible.
Tuesday
June 3
2014
R4D’s market dynamics team works to align the needs of manufacturers, countries, financiers and regulators. The goal is to ensure that the most marginalized populations have reliable, high-quality, affordable access to products such as HIV/AIDS treatment, neglected diseases drugs and sanitation technologies.
Monday
June 9
2014
Investors are increasingly looking at health care in developing countries as an investable sector instead of one dependent on government or philanthropic subsidy, making it more important to find business models that work to ensure the market dynamics are favorable for investment.
Thursday
July 10
2014
CycleTel helps women access family planning on their phones. But before its developers at Georgetown University could begin with product development, they had to understand the nuances of delivering personal information on a mobile phone.
Tuesday
July 22
2014
Angela Rastegar Campbell / Ya’ir Aizenman
Vaccines are effective and relatively inexpensive health interventions but, for a variety of reasons, many potential vaccines are never developed, distributed or tailored to work effectively in the Global South. Recent risk reduction measures, however, show promise toward reducing vaccine prices and increasing access while engaging manufacturers and stimulating innovation in the market.
Thursday
August 7
2014
After working with a number of key players in the water and sanitation business, the author, Urvashi Prasad, has compiled a list of factors that could enable for-profit players to fulfill the dual objectives of making profits and doing social good by bringing essential services to people who need them the most.
Wednesday
September 17
2014
Professor Patricia Danzon of The Wharton School, University of Pennsylvania, discusses differential pricing -- sometimes called price discrimination -- which she maintains increases utilization of medicines and, therefore, overall social welfare.
Thursday
September 18
2014
?In Part 1 of her interview with NBHC, professor Patricia Danzon of The Wharton School, University of Pennsylvania laid out some of the advantages of differential pricing in pharmaceuticals. In Part 2, she describes how the concept works in practice, including the key role of politics in its implementation.
Thursday
October 30
2014
While market shaping can be transformative, it’s not a cure-all. USAID’s primer offers a disciplined approach to examining a health product market and evaluating whether and how market shaping could increase access for end users.
Thursday
November 6
2014
Prashant Yadav / Amanda Glassman
The most valuable currency in global health programs today is accurate and reliable data, but such data doesn’t exist for most low-income and lower-middle-income countries – primarily because it’s expensive. The authors discuss why, and how, more data might become available.
Thursday
November 13
2014
The Access to Medicine Index, which is published every two years and independently ranks pharmaceutical companies’ efforts to improve access to medicine in developing countries, will be released on Monday.
Monday
December 1
2014
In the first of a two-part post, the author says tiered pricing is feasible when markets are separable and when the seller exerts significant power over pricing, such as when there is limited or no competition due to patent protection, data exclusivity or other barriers to market entry. But there are several reasons tiered pricing can be both ethically and practically problematic for pharmaceuticals.
Tuesday
December 2
2014
In Part 2 of a two-part post, Harvard’s Suerie Moon suggests four ways tiered-pricing policies for pharmaceuticals might be improved in the short-to-medium term, and also highlights some alternatives – including rewarding innovation.
Tuesday
December 9
2014
Developing tools for improving markets to serve larger societal needs requires a deep understanding of the market context and tailor-made analysis. However, making comparisons with other markets and having close interactions with those who work on a completely different market can be immensely valuable.
Tuesday
December 23
2014
The lead researcher with the Access to Medicine Index, which ranks pharmaceutical companies’ efforts to improve access to medicine for priority diseases in developing countries, explains how and why the Index’s pricing methodology evolved from measuring tiered-pricing strategies to measure what the Index terms “equitable pricing strategies” instead.
Monday
January 12
2015
David Ripin / Danielle Kuczynski
By actively engaging stakeholders on the supply and demand sides of the market, The Clinton Health Access Initiative helps overcome access challenges and gets health care commodities to the people who need them the most, write CHAI leaders David Ripin and Danielle Kuczynski. But what does ‘market shaping’ do to help those most in need?
Tuesday
January 13
2015
David Ripin / Danielle Kuczynski
A focused market-shaping approach remains a relatively young and rapidly evolving dimension of global health, but CHAI and its partners have demonstrated that market shaping can be used to impact outcomes and achieve significant savings for governments and donors.
